These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25622059)

  • 1. Depot Medroxyprogesterone Acetate Use Is Associated With Elevated Innate Immune Effector Molecules in Cervicovaginal Secretions of HIV-1-Uninfected Women.
    Guthrie BL; Introini A; Roxby AC; Choi RY; Bosire R; Lohman-Payne B; Hirbod T; Farquhar C; Broliden K
    J Acquir Immune Defic Syndr; 2015 May; 69(1):1-10. PubMed ID: 25622059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Cervical CD4
    Lajoie J; Tjernlund A; Omollo K; Edfeldt G; Röhl M; Boily-Larouche G; Cheruiyot J; Kimani M; Kimani J; Oyugi J; Broliden K; Fowke KR
    AIDS Res Hum Retroviruses; 2019 Mar; 35(3):236-246. PubMed ID: 30585733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity.
    Zalenskaya IA; Chandra N; Yousefieh N; Fang X; Adedipe OE; Jackson SS; Anderson SM; Mauck CK; Schwartz JL; Thurman AR; Doncel GF
    J Clin Invest; 2018 Oct; 128(10):4622-4638. PubMed ID: 30222141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.
    Heffron R; Mugo N; Were E; Kiarie J; Bukusi EA; Mujugira A; Frenkel LM; Donnell D; Ronald A; Celum C; Baeten JM;
    AIDS; 2014 Nov; 28(18):2771-6. PubMed ID: 25493602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Hormonal Contraception on Cervicovaginal Mucosal End Points Associated with HIV Acquisition.
    Thurman A; Chandra N; Schwartz JL; Brache V; Chen BA; Asin S; Rollenhagen C; Herold BC; Fichorova RN; Hillier SL; Weiner DH; Mauck C; Doncel GF
    AIDS Res Hum Retroviruses; 2019 Sep; 35(9):853-864. PubMed ID: 30997816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices.
    Birse KD; Romas LM; Guthrie BL; Nilsson P; Bosire R; Kiarie J; Farquhar C; Broliden K; Burgener AD
    J Infect Dis; 2017 Feb; 215(4):590-598. PubMed ID: 28011908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Contribution of Cervicovaginal Infections to the Immunomodulatory Effects of Hormonal Contraception.
    Fichorova RN; Chen PL; Morrison CS; Doncel GF; Mendonca K; Kwok C; Chipato T; Salata R; Mauck C
    mBio; 2015 Sep; 6(5):e00221-15. PubMed ID: 26330510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Hormonal Contraceptive Use and HIV on Cervicovaginal Cytokines and Microbiota in Malawi.
    Haddad LB; Tang JH; Davis NL; Kourtis AP; Chinula L; Msika A; Tegha G; Hosseinipour MC; Nelson JAE; Hobbs MM; Gajer P; Ravel J; De Paris K
    mSphere; 2023 Feb; 8(1):e0058522. PubMed ID: 36622252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial.
    Chinula L; Nelson JAE; Wiener J; Tang JH; Hurst S; Tegha G; Msika A; Ellington S; Hosseinipour MC; Mataya R; Haddad LB; Kourtis AP
    Contraception; 2018 Sep; 98(3):193-198. PubMed ID: 29746813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of etonogestrel implant use on T-cell and cytokine profiles in the female genital tract and blood.
    Haddad LB; Swaims-Kohlmeier A; Mehta CC; Haaland RE; Brown NL; Sheth AN; Chien H; Titanji K; Achilles SL; Lupo D; Hart CE; Ofotokun I
    PLoS One; 2020; 15(3):e0230473. PubMed ID: 32214321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception.
    Heffron R; Parikh UM; Penrose KJ; Mugo N; Donnell D; Celum C; Mellors JW; Baeten JM;
    AIDS Behav; 2017 Jul; 21(7):2173-2179. PubMed ID: 27699594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of menopause on the innate antiviral activity of cervicovaginal lavage.
    Chappell CA; Isaacs CE; Xu W; Meyn LA; Uranker K; Dezzutti CS; Moncla BJ; Hillier SL
    Am J Obstet Gynecol; 2015 Aug; 213(2):204.e1-6. PubMed ID: 25818668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities.
    Kourtis AP; Haddad L; Tang J; Chinula L; Hurst S; Wiener J; Ellington S; Nelson JA; Corbett A; De Paris K; King CC; Hosseinipour M; Hoffman IF; Jamieson DJ
    Contemp Clin Trials; 2017 Jan; 52():27-34. PubMed ID: 27836505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
    Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
    Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Vaginal Microbiota and Immune Mediators in HIV-1-Seronegative Kenyan Women Initiating Depot Medroxyprogesterone Acetate.
    Roxby AC; Fredricks DN; Odem-Davis K; Ásbjörnsdóttir K; Masese L; Fiedler TL; De Rosa S; Jaoko W; Kiarie JN; Overbaugh J; McClelland RS
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):359-66. PubMed ID: 26914908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.
    Nanda K; Callahan R; Taylor D; Wang M; Agot K; Jenkins D; Van Damme L; Dorflinger L;
    Contraception; 2016 Jul; 94(1):40-7. PubMed ID: 26972780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships.
    Levinson P; Choi RY; Cole AL; Hirbod T; Rhedin S; Payne B; Guthrie BL; Bosire R; Cole AM; Farquhar C; Broliden K
    PLoS One; 2012; 7(2):e31996. PubMed ID: 22389677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal contraception and HIV acquisition risk: implications for individual users and public policies.
    Jain AK
    Contraception; 2012 Dec; 86(6):645-52. PubMed ID: 22541635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion.
    Morrison C; Fichorova RN; Mauck C; Chen PL; Kwok C; Chipato T; Salata R; Doncel GF
    J Acquir Immune Defic Syndr; 2014 Jun; 66(2):109-17. PubMed ID: 24413042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-omics analysis of the cervical epithelial integrity of women using depot medroxyprogesterone acetate.
    Bradley F; Franzén Boger M; Kaldhusdal V; Åhlberg A; Edfeldt G; Lajoie J; Bergström S; Omollo K; Damdimopoulos A; Czarnewski P; Månberg A; Oyugi J; Kimani J; Nilsson P; Fowke K; Tjernlund A; Broliden K
    PLoS Pathog; 2022 May; 18(5):e1010494. PubMed ID: 35533147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.